Gradient Investments LLC Buys Shares of 55,473 Insulet Corporation $PODD

Gradient Investments LLC purchased a new stake in shares of Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 55,473 shares of the medical instruments supplier’s stock, valued at approximately $17,429,000.

Several other institutional investors have also made changes to their positions in PODD. Captrust Financial Advisors lifted its holdings in shares of Insulet by 24.1% during the 4th quarter. Captrust Financial Advisors now owns 2,185 shares of the medical instruments supplier’s stock valued at $570,000 after buying an additional 425 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Insulet by 7.0% during the 4th quarter. Janus Henderson Group PLC now owns 7,846 shares of the medical instruments supplier’s stock valued at $2,049,000 after buying an additional 511 shares during the last quarter. NorthRock Partners LLC acquired a new stake in shares of Insulet during the 4th quarter valued at about $267,000. Nissay Asset Management Corp Japan ADV lifted its holdings in shares of Insulet by 0.9% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 8,414 shares of the medical instruments supplier’s stock valued at $2,231,000 after buying an additional 78 shares during the last quarter. Finally, ProShare Advisors LLC lifted its holdings in shares of Insulet by 12.3% during the 4th quarter. ProShare Advisors LLC now owns 10,614 shares of the medical instruments supplier’s stock valued at $2,771,000 after buying an additional 1,159 shares during the last quarter.

Wall Street Analysts Forecast Growth

PODD has been the subject of several research reports. Truist Financial initiated coverage on Insulet in a report on Monday, June 16th. They set a “buy” rating and a $365.00 price target for the company. The Goldman Sachs Group began coverage on Insulet in a report on Friday, May 30th. They issued a “buy” rating and a $380.00 target price for the company. Barclays boosted their target price on Insulet from $266.00 to $300.00 and gave the stock an “equal weight” rating in a report on Thursday, August 21st. Oppenheimer boosted their target price on Insulet from $324.00 to $365.00 and gave the stock an “outperform” rating in a report on Monday, September 8th. Finally, Royal Bank Of Canada boosted their target price on Insulet from $330.00 to $350.00 and gave the stock an “outperform” rating in a report on Friday, August 8th. Sixteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $335.12.

Insulet Stock Up 1.1%

Shares of PODD stock opened at $341.78 on Monday. Insulet Corporation has a 12 month low of $225.37 and a 12 month high of $353.50. The firm has a market cap of $24.06 billion, a PE ratio of 103.88, a price-to-earnings-growth ratio of 2.84 and a beta of 1.36. The stock has a 50 day moving average of $311.59 and a 200-day moving average of $292.31. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. During the same period in the previous year, the company earned $0.55 earnings per share. The company’s quarterly revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

Insider Buying and Selling

In other news, SVP Prem Singh sold 687 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.